Special Issue

Application of Radiolabeled Agents: Imaging, Therapy, Multimodal Approaches and Beyond

Message from the Guest Editors

The journal *Pharmaceuticals* is planning to publish a Special Issue covering the topic of "Application of Radiolabeled Agents: Imaging, Therapy, Multimodal Approaches, and beyond", and I am cordially inviting you to contribute an article to this volume describing your latest research. Reviews are welcome as well. Usually, the application of radiolabeled compounds is associated with conventional nuclear medicine imaging by means of PET (positron emission tomography) or SPECT (single photon emission computed tomography). Indeed, this is still the main application of these agents; however, radiolabeled compounds are also becoming increasingly important in theranostic applications for endoradiotherapy, carrying \(\mathbb{\Bar}\)-- or \(\mathbb{\Bar}\)-emitters. Another aspect is the combination of imaging techniques using radiotracers, either combined in the form of multimodal imaging, or also in separate, complementary modalities. The aim of this Special Issue is to bring together the latest developments in the aforementioned areas of radiolabeled agents and applications, while also highlighting new trends beyond conventional applications.

Guest Editors

Prof. Dr. Carmen Wängler

Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany

Prof. Dr. Björn Wängler

Molecular Imaging & Radiochemistry, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany

Deadline for manuscript submissions

closed (15 September 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/123898

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

